

Cynthia Levy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/238363/publications.pdf>

Version: 2024-02-01

89
papers

3,188
citations

201674

27
h-index

168389

53
g-index

90
all docs

90
docs citations

90
times ranked

2877
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2019, 69, 394-419.	7.3	507
2	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	1.3	355
3	The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1734-1740.	2.3	300
4	Seladelpar (MBX-8025), a selective PPAR- γ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 716-726.	8.1	126
5	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology</i> , 2019, 69, 684-698.	7.3	121
6	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 94-101.	3.7	111
7	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> , 2016, 64, 189-199.	7.3	101
8	EASL Clinical Practice Guidelines on sclerosing cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 761-806.	3.7	84
9	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 1344-1354.	3.7	77
10	Primary Sclerosing Cholangitis: Epidemiology, Natural History, and Prognosis. <i>Seminars in Liver Disease</i> , 2006, 26, 022-030.	3.6	74
11	Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 296-306.	1.5	69
12	Cholestatic liver diseases: new targets, new therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878740.	3.2	61
13	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	4.4	57
14	Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , 2021, 73, 2099-2109.	7.3	56
15	Hispanics With Primary Biliary Cirrhosis Are More Likely to Have Features of Autoimmune Hepatitis and Reduced Response to Ursodeoxycholic Acid Than Non-Hispanics. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1398-1405.	4.4	55
16	Novel and emerging therapies for cholestatic liver diseases. <i>Liver International</i> , 2018, 38, 1520-1535.	3.9	53
17	Prevalence and Predictors of Esophageal Varices in Patients With Primary Biliary Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 803-808.	4.4	48
18	Recurrent and De Novo Autoimmune Liver Diseases. <i>Clinics in Liver Disease</i> , 2011, 15, 859-878.	2.1	44

#	ARTICLE	IF	CITATIONS
19	Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 830-839.	3.7	43
20	Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. <i>Journal of Autoimmunity</i> , 2019, 101, 26-34.	6.5	40
21	Primary Biliary Cirrhosis is More Severe in Overweight Patients. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, e28-e32.	2.2	38
22	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1138-1146.	3.7	37
23	Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis. <i>Hepatology</i> , 2021, 74, 879-891.	7.3	36
24	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 353-364.	3.7	36
25	Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2017, 37, 305-313.	3.6	32
26	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. <i>Liver International</i> , 2022, 42, 112-123.	3.9	31
27	Hepatic Sarcoidosis: Natural History and Management Implications. <i>Frontiers in Medicine</i> , 2019, 6, 232.	2.6	29
28	Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1913-1923.	0.4	28
29	Primary Biliary Cirrhosis. <i>Clinics in Liver Disease</i> , 2013, 17, 229-242.	2.1	27
30	Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. <i>Liver International</i> , 2022, 42, 607-614.	3.9	26
31	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1248-1257.	4.4	25
32	Safety of fibrates in cholestatic liver diseases. <i>Liver International</i> , 2021, 41, 1335-1343.	3.9	25
33	Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e109.	2.5	23
34	FXR Agonists: From Bench to Bedside, a Guide for Clinicians. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3395-3404.	2.3	22
35	Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 76, 75-85.	3.7	22
36	Understanding and Treating Pruritus in Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 517-532.	2.1	21

#	ARTICLE	IF	CITATIONS
37	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
38	Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 591-593.	4.4	20
39	Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. <i>Liver International</i> , 2020, 40, 382-392.	3.9	19
40	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2295-2304.e2.	4.4	18
41	Endoscopic Management of Primary Sclerosing Cholangitis. <i>Annals of Hepatology</i> , 2017, 16, 842-850.	1.5	15
42	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	4.4	15
43	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	3.9	15
44	Cholestatic Liver Diseases After Liver Transplant. <i>Clinics in Liver Disease</i> , 2017, 21, 403-420.	2.1	14
45	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1105-1116.	7.3	14
46	Gender Differences in Hepatology Medical Literature. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3014-3022.	2.3	13
47	A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale. <i>Hepatology Communications</i> , 2018, 2, 484-491.	4.3	12
48	Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 15-46.	0.8	11
49	Tu1002 Fenofibrate Improves Alkaline Phosphatase in Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2013, 144, S-1028-S-1029.	1.3	10
50	Use of Butorphanol as Treatment for Cholestatic Itch. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1693-1699.	2.3	10
51	Anti-mitochondrial Antibody-Negative Primary Biliary Cholangitis Is Part of the Same Spectrum of Classical Primary Biliary Cholangitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3305-3312.	2.3	9
52	Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. <i>Digestive Diseases and Sciences</i> , 2023, 68, 995-1005.	2.3	9
53	Ethnicity predicts metabolic syndrome after liver transplant. <i>Hepatology International</i> , 2013, 7, 741-748.	4.2	8
54	Novel Therapies on Primary Biliary Cirrhosis. <i>Clinics in Liver Disease</i> , 2016, 20, 113-130.	2.1	8

#	ARTICLE	IF	CITATIONS
55	UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 232-241.	0.8	8
56	Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute intermittent porphyria. <i>Genetics in Medicine</i> , 2020, 22, 590-597.	2.4	8
57	Role of Antinuclear Antibodies in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1604-1606.	0.4	8
58	Primary Biliary Cholangitis Guidance Update: Implications for Liver Transplantation. <i>Liver Transplantation</i> , 2018, 24, 1508-1511.	2.4	7
59	Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. <i>Journal of Hepatology</i> , 2020, 73, S464-S465.	3.7	7
60	Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis. <i>Liver International</i> , 2022, 42, 384-393.	3.9	7
61	Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. <i>Annals of Hepatology</i> , 2022, 27, 100546.	1.5	6
62	Hispanic Patients with Primary Biliary Cholangitis Have Decreased Access to Care Compared to Non-Hispanics. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-6.	1.4	6
63	Evolving role of obeticholic acid in primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1666-1668.	7.3	5
64	Validating a novel algorithm to identify patients with autoimmune hepatitis in an administrative database. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1168-1174.	1.9	4
65	Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 818089.	3.5	4
66	Medical management of primary sclerosing cholangitis. <i>Clinical Liver Disease</i> , 2014, 3, 48-51.	2.1	3
67	Primary biliary cholangitis: Treatment options finally expand. <i>Hepatology</i> , 2017, 65, 1405-1407.	7.3	3
68	Fibrates for Primary Biliary Cholangitis: What's All the Hype?. <i>Annals of Hepatology</i> , 2017, 16, 704-706.	1.5	3
69	Itching to Know: Role of Fibrates in PBC. <i>American Journal of Gastroenterology</i> , 2018, 113, 56-57.	0.4	3
70	Update in the Care and Management of Patients with Primary Sclerosing Cholangitis. <i>Current Gastroenterology Reports</i> , 2018, 20, 29.	2.5	3
71	Use of Fenofibrate for patients with primary Sclerosing Cholangitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e33-e36.	1.5	3
72	Novel Therapies for Managing Cholestasis. <i>Clinical Liver Disease</i> , 2020, 15, 95-99.	2.1	3

#	ARTICLE	IF	CITATIONS
73	Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. <i>Hepatology</i> , 2021, 73, 887-889.	7.3	3
74	Safety considerations for the management of cholestatic itch. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 915-924.	2.4	3
75	Novel Therapies for Cholestatic Liver Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 493-496.	0.1	3
76	Liver Transplant: Reaching the Half Century. <i>Clinics in Liver Disease</i> , 2011, 15, xi-xii.	2.1	1
77	Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2013, 17, xiii-xiv.	2.1	1
78	Can we avoid primary sclerosing cholangitis recurrence?. <i>Liver Transplantation</i> , 2016, 22, 12-13.	2.4	1
79	Portal Cavernoma Mimicking Pancreatic Malignancy. <i>ACG Case Reports Journal</i> , 2018, 5, e15.	0.4	1
80	Ethnic and Racial Differences in Autoimmune Liver Diseases. <i>Current Hepatology Reports</i> , 2018, 17, 135-142.	0.9	1
81	Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. <i>Canadian Liver Journal</i> , 2021, 4, 401-425.	0.9	1
82	Is Ursodeoxycholic Acid Really a Posttransplant Panacea?. <i>Liver Transplantation</i> , 2021, 27, 791-793.	2.4	1
83	Advances in Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2016, 20, xiii-xiv.	2.1	0
84	Primary Biliary Cholangitis: A New Era. <i>Clinics in Liver Disease</i> , 2018, 22, xiii-xiv.	2.1	0
85	Editorial: biochemical responses do not tell the whole story in primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 177-178.	3.7	0
86	REPLY:. <i>Hepatology</i> , 2021, 74, 2308-2308.	7.3	0
87	REPLY:. <i>Hepatology</i> , 2021, 74, 2322-2323.	7.3	0
88	Primary Biliary Cholangitis. , 2018, , 610-625.e3.		0
89	Primary Biliary Cholangitis. <i>Current Treatment Options in Gastroenterology</i> , 0, , .	0.8	0